1. Most Discussed
  2. Gainers & Losers
CUV $6.68

company presentation

  1. invest

    3,411 posts.
    I looked over their company presentation they have achieved and it is inevitable as mentioned in the report that a Big Phar Company will seek to partner with and already they have been approached by companies regarding the Melanotan. They are seeking FDA approval next month, which will be another boost. I dont see them seeking extra funds as they mentioned they will commercialise their developement through a partnership. The company has NO Borrowings and Debt and shares on issue is small considering other Biotec companies. And they have a world patent rights which means no competion. Looks good to me. This stock is bound to reach over the $1.00 mark again and I feel confident that will go even further in share price. Anothe good Aussie invention.

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top